SEC
SlamSEC
Search
Browse
Earnings
Sagimet Biosciences Inc. — SlamSEC
Sagimet Biosciences Inc.
Nasdaq:
SGMT
Pharmaceutical Preparations
·
SAN MATEO, CA
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Summary Financials
Revenue
$2.0M
+0.0% YoY
FY 2024
Adj. EBITDA
—
Net Income
-$45.6M
-2278.3% margin
FY 2025
EPS (Diluted)
-$1.45
FY 2025
Stock Price
$5.21
-2.4%
2026-03-13
52W Range
$1.73 – $11.41
P/E Ratio
-3.6x
Market Cap
$159.8M
Cash
$75.8M
FY 2025
Total Debt
—
Net Cash
$75.8M
FY 2024
Enterprise Value
$84.0M
Debt / EBITDA
—
EV / EBITDA
—
Employees
—
CEO
Happel David
CFO
Chauche Thierry